MX373624B - Formulación de ceritinib. - Google Patents

Formulación de ceritinib.

Info

Publication number
MX373624B
MX373624B MX2016015736A MX2016015736A MX373624B MX 373624 B MX373624 B MX 373624B MX 2016015736 A MX2016015736 A MX 2016015736A MX 2016015736 A MX2016015736 A MX 2016015736A MX 373624 B MX373624 B MX 373624B
Authority
MX
Mexico
Prior art keywords
composition
ceritinib
binder
formulation
povidone
Prior art date
Application number
MX2016015736A
Other languages
English (en)
Spanish (es)
Other versions
MX2016015736A (es
Inventor
Sebastian Breulles
Simon Ensslin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX373624(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016015736A publication Critical patent/MX2016015736A/es
Publication of MX373624B publication Critical patent/MX373624B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
MX2016015736A 2014-05-29 2015-05-27 Formulación de ceritinib. MX373624B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29
PCT/IB2015/053966 WO2015181739A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Publications (2)

Publication Number Publication Date
MX2016015736A MX2016015736A (es) 2017-03-16
MX373624B true MX373624B (es) 2020-05-22

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015736A MX373624B (es) 2014-05-29 2015-05-27 Formulación de ceritinib.

Country Status (27)

Country Link
US (4) US20170112834A1 (enExample)
EP (1) EP3148513B1 (enExample)
JP (3) JP6679578B2 (enExample)
KR (1) KR20170008239A (enExample)
CN (1) CN106456640B (enExample)
AR (1) AR100625A1 (enExample)
AU (3) AU2015265470A1 (enExample)
BR (1) BR112016027580A8 (enExample)
CA (1) CA2948291A1 (enExample)
CL (1) CL2016003047A1 (enExample)
DK (1) DK3148513T3 (enExample)
EA (1) EA036922B1 (enExample)
EC (1) ECSP16096826A (enExample)
ES (1) ES2792574T3 (enExample)
HU (1) HUE048950T2 (enExample)
IL (1) IL248835B (enExample)
MX (1) MX373624B (enExample)
PE (1) PE20170313A1 (enExample)
PH (1) PH12016502272A1 (enExample)
PL (1) PL3148513T3 (enExample)
PT (1) PT3148513T (enExample)
SG (1) SG11201609208UA (enExample)
SI (1) SI3148513T1 (enExample)
TN (1) TN2016000484A1 (enExample)
TW (1) TWI721946B (enExample)
UY (1) UY36140A (enExample)
WO (1) WO2015181739A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3148513T1 (sl) 2014-05-29 2020-07-31 Novartis Ag Formulacija ceritiniba
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
MX2008011459A (es) 2006-03-06 2008-09-24 Wyeth Corp Formulaciones y procesos para tabletas.
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
ME00811B (me) * 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
KR101364277B1 (ko) * 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
WO2010025796A1 (en) 2008-09-04 2010-03-11 Cargill Incorporated Tabletting of ervthritol
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
WO2011020526A1 (en) 2009-08-18 2011-02-24 Cargill, Incorporated Tabletting of erythritol and isomalt
CN106890147A (zh) * 2010-05-11 2017-06-27 田边三菱制药株式会社 含1‑(β‑D‑吡喃葡糖基)‑3‑(苯基噻吩基甲基)苯化合物的片剂
MX2013002326A (es) 2010-09-07 2013-03-18 Cargill Inc Mezcla solidificada de alcohol de azucar.
SI3148513T1 (sl) 2014-05-29 2020-07-31 Novartis Ag Formulacija ceritiniba

Also Published As

Publication number Publication date
JP2022078236A (ja) 2022-05-24
CN106456640A (zh) 2017-02-22
US20170112834A1 (en) 2017-04-27
ES2792574T3 (es) 2020-11-11
PE20170313A1 (es) 2017-04-18
TW201613580A (en) 2016-04-16
IL248835B (en) 2020-05-31
EA201692310A1 (ru) 2017-04-28
SI3148513T1 (sl) 2020-07-31
CA2948291A1 (en) 2015-12-03
US20190022095A1 (en) 2019-01-24
SG11201609208UA (en) 2016-12-29
PH12016502272A1 (en) 2017-02-06
JP7084955B2 (ja) 2022-06-15
AU2019232937B2 (en) 2020-10-15
US20200009141A1 (en) 2020-01-09
PT3148513T (pt) 2020-05-27
US11000523B2 (en) 2021-05-11
DK3148513T3 (da) 2020-05-25
JP2020114834A (ja) 2020-07-30
CN106456640B (zh) 2021-05-14
US12357630B2 (en) 2025-07-15
UY36140A (es) 2016-01-08
MX2016015736A (es) 2017-03-16
AU2019232937A1 (en) 2019-10-10
WO2015181739A1 (en) 2015-12-03
ECSP16096826A (es) 2018-04-30
JP6679578B2 (ja) 2020-04-15
EA036922B1 (ru) 2021-01-15
JP2017520619A (ja) 2017-07-27
IL248835A0 (en) 2017-01-31
CL2016003047A1 (es) 2017-04-07
AU2015265470A1 (en) 2016-11-24
EP3148513B1 (en) 2020-02-26
KR20170008239A (ko) 2017-01-23
AU2018203007B2 (en) 2019-07-18
TWI721946B (zh) 2021-03-21
BR112016027580A2 (pt) 2017-08-15
BR112016027580A8 (pt) 2021-06-29
US20210154194A1 (en) 2021-05-27
EP3148513A1 (en) 2017-04-05
PL3148513T3 (pl) 2020-08-24
TN2016000484A1 (en) 2018-04-04
AU2018203007A1 (en) 2018-05-17
HUE048950T2 (hu) 2020-09-28
AR100625A1 (es) 2016-10-19

Similar Documents

Publication Publication Date Title
CO2019000613A2 (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CU20150071A7 (es) Composición de liberación demorada que comprende biguanida
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX2017007699A (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
MX2016013236A (es) Formulacion inmunosupresora.
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
HK1231390A1 (zh) 用於局部给药的药用组合物
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
MX373624B (es) Formulación de ceritinib.
GT201300032A (es) Composicion farmaceutica de liberacion prolongada de trimetazidina
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
BR112016028081A2 (pt) Novos compostos como agentes antituberculares
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico

Legal Events

Date Code Title Description
FG Grant or registration